Advances in the management of insomnia

Bibliography

• Handbook of behavioral state control Lydic R, Baghdoyan HA (Eds), CRC Press, Boca Raton, FL, USA (1999).
   Google Scholar
• ••An excellent book, containing importantbasic information about sleep.
   Google Scholar
• HOBSON JA, PACE-SCHOTT EF: The cognitive neuroscience of sleep: neuronal systems, consciousness and learning. Nat. Rev Neurosci. (2002) 3(9):679–693.
   PubMed Web of Science ®Google Scholar
• ANCOLI-ISRAEL S, ROTH T: Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. Sleep (2000) 22:S347–S353.
   Web of Science ®Google Scholar
• Diagnostic Classification Steering Committee, Thorpy MJ, Chairman. International Classification of Sleep Disorders: Diagnostic and Coding Manual. Rochester, MN: American Sleep Disorders Association (1997).
   Google Scholar
• SMITH MT, PERLIS ML, PARK A et al: Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am. I Psychiatry (2002) 159(1):5–11.
   PubMed Web of Science ®Google Scholar
• SKENE DJ: Optimization of light and melatonin to phase-shift human circadian rhythms. J. Neuroendocrinol (2003) 15 (4):438–441.
   PubMed Web of Science ®Google Scholar
• •Useful information on therapeutic strategies for phase shift.
   Google Scholar
• LEWY AJ, EMENS JS, SACK RL et al.: Low, but not high, doses of melatonin entrained a free-running blind person with a long circadian period. Chronobiol(2002) 19(3):649–658.
   Google Scholar
• HAPPE S, TRENKWALDER C: Role of dopamine receptor agonists in the treatment of restless legs syndrome. CNS Drugs (2004)18(1):27–36.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review of thepharmacotherapy of restless leg syndrome.
   Google Scholar
• SMITH MT, PERLIS ML, PARK A et al.: Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am. .1. Psychiatry (2002) 159(1):5–11.
   Google Scholar
• MONTI JM, MONTI D: Sleep disturbance in generalized anxiety disorder and its treatment. Sleep Med. Rev (2000) 4(3):263–276.
   PubMed Web of Science ®Google Scholar
• ZHDANOVA IV, LYNCH HJ, WURTMAN RJ: Melatonin: a sleep promoting hormone. Sleep (1997) 20(10):899–907.
   PubMed Web of Science ®Google Scholar
• ROEHRS T, ROTH T: Hypnotics: an update. Carr: Nemo]. Neurosci. Rep. (2003) 3(2):181–184.
   PubMedGoogle Scholar
• WINOKUR A, DEMARTINIS NA 3rd, MCNALLY DP et al.: Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. I Clin. Psychiatry (2003) 64(10):1224–1229.
   Google Scholar
• GYLLENHAAL C, MERRITT SL, PETERSON SD, BLOCK KI, GOCHENOUR T: Efficacy and safety of herbal stimulants and sedatives in sleep disorders. Sleep Med. Rev (2000) 4(3):229–251.
   PubMed Web of Science ®Google Scholar
• •Detailed information on herbal hypnotics.
   Google Scholar
• ZIEGLER G, PLOCH M, MIETTINEN-BAUMANN A,COLLET W: Efficacy and tolerability of valerian extract LI 156 compared with oxazepam in the treatment of non-organic insomnia-a randomized, double-blind, comparative clinical study. Eur: I Med. Res. (2002) 7(11):480–486.
   PubMed Web of Science ®Google Scholar
• SATEIA MJ, DOGHRAMJI K, HAURI PJ, MORIN CM: Evaluation of chronic insomnia. An American Academy of Sleep Medicine review. Sleep (2000) 23 (2):243–308.
   Google Scholar
• GAUILLARD J, CHEREF S, VACHERONTRYSTRAM MN et al.: Chloral hydrate: a hypnotic best forgotten? Encephale (2002) 28:200–204.
   Google Scholar
• BUFFET-JERROTT SE, STEWART SH: Cognitive and sedative effects of benzodiazepine use. Curc Pharm. Des. (2002) 8(1):45–58.
   PubMed Web of Science ®Google Scholar
• LADER MH: Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified? Eur. Neuropsychopharmacol (1999) 9:S399–S405.
   Web of Science ®Google Scholar
• CUMMINGS RG, LE COUTEUR DG: Benzodiazepines and risk of hip fractures in older people: a review of the evidence. CNS Drugs (2003) 17(11):825–837.
   PubMed Web of Science ®Google Scholar
• SALVA P, COSTA J: Clinicalpharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. Clin. Pharmacokinet. (1995) 29(3):142–153.
   PubMed Web of Science ®Google Scholar
• GREENBLATT DJ, HARMATZ JS, VON MOLTKE LL et al: Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. Pharmacol The]: (1998) 64(5):553–561.
   Web of Science ®Google Scholar
• DOOLEY M, PLOSKER GL: Zaleplon: a review of its use in the treatment of insomnia. Drugs (2000) 60(2):413–445.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ C, MARTIN C, GIMMENEZ F et al.: Clinical pharmacokinetics of zopiclone. Clin. Pharmacokinet. (1995) 29(6):431–441.
   PubMed Web of Science ®Google Scholar
• ISRAEL AG, KRAMER JA: Safety of zaleplon in the treatment of insomnia. Ann. Pharmacother. (2002) 36(5):852–859.
   PubMed Web of Science ®Google Scholar
• WAGNER J, WAGNER ML: Non-benzodiazepines for the treatment of insomnia. Sleep Med. Rev (2000) 4(6):551–581.
   PubMed Web of Science ®Google Scholar
• ERMAN MK, ERWIN CW, GENGO FM et al.: Comparative efficacy of zolpidem and temazepam in transient insomnia. Psychopharmacology (2001) 16(2):169–176.
   Web of Science ®Google Scholar
• HAJAK G, MULLER WE,WITTCHEN HU et al.: Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction (2003) 98(10):1371–1378.
   Google Scholar
• VOLDERHOLZER U, RIEMANN D, HORNYAK M et al.: double-blind, randomized and placebo-controlled study on the polysomnographic withdrawal effects of zopiclone, zolpidem and triazolam in healthy subjects. Eur. Arch. Psychiatry Gin. Neurosci. (2001) 251(3):117–123.
   PubMed Web of Science ®Google Scholar
• TONER LC, TSAMBIRAS BM, CATALANO G et al.: Central nervous system side effects associated with zolpidem treatment. Clin. Neuropharmacol (2000) 23(1):54–58.
   PubMed Web of Science ®Google Scholar
• MORGENTHALER TI, SILBER MH: Amnestic sleep-related eating disorder associated with zolpidem.Sleep Med. (2002) 3(4):323–327.
   PubMedGoogle Scholar
• HUANG CL, CHANG CJ, HUNG CF et al.: Zolpidem-induced distortion in visual perception. Ann. Pharmacother: (2003) 37(5):683–686.
   PubMed Web of Science ®Google Scholar
• VERMEEREN A: Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs (2004) 18(5):297–328.
   PubMed Web of Science ®Google Scholar
• DANJOU P, PATY I, FRUNCILLO R et al.: A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening. Br. Clin. Pharmacol (1999) 48(3):367–374.
   PubMed Web of Science ®Google Scholar
• WANG JS, DEVANE CL:Pharmacokinetics and drug interactions of the sedative hypnotics. Psychopharmacol Bull. (2003) 37(1):10–29.
   PubMedGoogle Scholar
• •Important details on drug interactions.
   Google Scholar
• HESSE LM, VON MOLTKE LL, GREENBLATT DJ: Clinically important drug interactions with zopiclone, zolpidem and zaleplon. CNS Drugs (2003) 17(7):513–532.
   PubMed Web of Science ®Google Scholar
• LERNER AB, CASE JD: Melatonin. Fed Proc 1960; 19:590–592.
   Google Scholar
• ANTON-TAY F, DIAZ JL,FERNANDEZ-GUARDIOLA A: On the effect of melatonin upon human brain. Its possible therapeutic implications.Life Sci. (1971) 10:841–850.
   Google Scholar
• WALDHAUSER F, SALETU B,TRINCHARD-LUGAN I: Sleep laboratory investigations on hypnotic properties of melatonin. Psychopharmacology (1990) 100:222–226.
   PubMed Web of Science ®Google Scholar
• TZISCHINSKI O, LAVIE P: Melatonin possesses time-dependent hypnotic effects. Sleep (1994) 17:638–645.
   PubMed Web of Science ®Google Scholar
• NAVE R, PELED R, LAVIE PMelatonin improves evening napping. Ear. Pharmacol(1995) 275:213–216.
   PubMed Web of Science ®Google Scholar
• ZHDANOVA IV, WURTMAN RJ, LYNCH HJ et al.: Sleep-inducing effects of low doses of melatonin ingested in the evening. Gin. Pharm. Ther. (1995) 57:552–558.
   Web of Science ®Google Scholar
• ZHDANOVA IV, WURTMAN RJ, MORABITO C, PIOTROVSKA VR, LYNCH HJ: Effects of low oral doses of melatonin, given 2-4 hours before habitual bedtime, on sleep in normal young humans. Sleep (1996) 19(5):423–431.
   PubMed Web of Science ®Google Scholar
• ATTENBURROW ME, COWEN PJ, SHARPLEY AL: Low dose melatonin improves sleep in healthy middle-aged subjects. Psychopharmacology (Berl) (1996) 126(2):179–181.
   PubMed Web of Science ®Google Scholar
• STONE BM, TURNER C, MILLS SL, NICHOLSON AN: Hypnotic activity of melatonin. Sleep (2000) 23(5):663–669.
   PubMed Web of Science ®Google Scholar
• JAN JE, ESPEZEL H, APPLETON RE: The treatment of sleep disorders with melatonin. Dev. Med. Child Neurol (1994) 36:97–107.
   PubMed Web of Science ®Google Scholar
• PILLAR G, SHAHAR E, PELED N et al: Melatonin improves sleep-wake patterns in psychomotor retarded children.Pediatr. Neurol (2000) 23(3):225–228.
   Google Scholar
• ZHDANOVA IV, WURTMAN RJ, WAGSTAFF J: Effects of low dose of melatonin on sleep in children with Angelman syndrome. j. Pediatr. Endocrinol Metab. (1999) 12(1):57–67.
   PubMed Web of Science ®Google Scholar
• •A representative study on the effects of melatonn in children with a specific neurological disorder.
   Google Scholar
• HAIMOV I, LAVIE P, LAUDON M et al: Melatonin replacement therapy of elderly insomniacs. Sleep (1995) 18(7):598–603.
   PubMed Web of Science ®Google Scholar
• ZHDANOVA IV, WURTMAN RJ, REGAN M et al: Melatonin treatment for age-related insomnia. J. Clin. Endocrinol Metab. (2001) 86(10):4727–4730.
   PubMed Web of Science ®Google Scholar
• •Useful information on the effects of melatonin in aged insomniacs.
   Google Scholar
• GARFINKEL D, ZISAPEL N,WAINSTEIN J, LAUD ON M: Facilitation of benzodiazepine discontinuation by melatonin: a new clinical approach. Arch. Intern. Med. (1999) 159(20):2456–2460.
   PubMed Web of Science ®Google Scholar
• SINGER C, TRACTENBERG RE, KAYE J et al: A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep (2003) 26(7):893–901.
   PubMed Web of Science ®Google Scholar
• DOLLINS AB, LYNCH HJ, WURTMAN RJ et al.: Effect of pharmacological daytime doses of melatonin on human mood and performance. Psychopharmacology (1993) 112:490–496.
   PubMed Web of Science ®Google Scholar
• HUGHES RJ, BADIA P: Sleep-promoting and hypothermic effects of daytime melatonin administration in humans. Sleep (1997) 20(2):124–131.
   PubMed Web of Science ®Google Scholar
• DOLBERG OT, HIRSCHMANN S, GRUNHAUS L: Melatonin for the treatment of sleep disturbances in major depressive disorder. Am.' Psychiatry(1998) 155(8):1119–1121.
   PubMed Web of Science ®Google Scholar
• HUGHES RJ, SACK RL, LEWY AJ: The role of melatonin and circadian phase in age-related sleep-maintenance insomnia: assessment in a clinical trial of melatonin replacement. Sleep (1998) 21(1):52–68.
   PubMed Web of Science ®Google Scholar
• ZHDANOVA IV, WANG S,LECLAIR OU, DANILOVA N: Melatonin promotes sleep-like behavior in zebrafish.Brain Res. (2001) 903 (1–2):263–268.
   Google Scholar
• ROGERS NL, KENNAWAY DJ, DAWSON D: Neurobehavioural performance effects of daytime melatonin and temazepam administration.Sleep Res. (2003) 12(3):207–212.
   PubMed Web of Science ®Google Scholar
• PAUL MA, GRAY G, KENNY G, PIGEAU RA: Impact of melatonin, zaleplon, zopiclone, and temazepam on psychomotor performance. Avial Space Environ. Med. (2003) 74(12):1263–1270.
   PubMed Web of Science ®Google Scholar
• http://www.sleepfoundation.orgNational Sleep Foundation. Sleep in America (1991). The Gallup Organization.
   Google Scholar
• ••An ongoing survey by professionalorganisaton, providing important updateson sleep and sleep alterations in US.
   Google Scholar